Pfizer fesoterodine "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's overactive bladder treatment fesoterodine is "approvable," according to Pfizer, which told Pharmaceutical Approvals Monthly that it received the letter during the week of Jan. 22. Pfizer acquired the agent from Schwarz in April (1Pharmaceutical Approvals Monthly May 2006, p. 26). Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012...